Individualizing drug dosage by using a random intercept linear model

Statistics in Medicine

Volumn 26, Issue 9, 2007, Pages 2052-2073

  Diaz, Francisco J ^a   Rivera, Tulia E ^b   Josiassen, Richard C ^c,d   de Leon, Jose ^e  

^a UNIVERSIDAD NACIONAL DE COLOMBIA   (Colombia)

^b UNIVERSIDAD INDUSTRIAL DE SANTANDER   (Colombia)

^c Arthur P Noyes Research Foundation   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e EASTERN STATE HOSPITAL   (United States)

Author keywords

Clozapine; Decision theory; Drug dosage individualization; Mixed models; Steady state drug plasma concentration; Therapeutic window

Indexed keywords

CLOZAPINE;

ALGORITHM; ANALYTICAL ERROR; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DECISION THEORY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; FEMALE; HUMAN; INDIVIDUALIZATION; MALE; MATHEMATICAL COMPUTING; OPTIMAL DRUG DOSE; RANDOMIZATION; SCHIZOPHRENIA; STATISTICAL MODEL; STEADY STATE;

ALGORITHMS; ANTIPSYCHOTIC AGENTS; CLOZAPINE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; LINEAR MODELS; MALE; PHARMACEUTICAL PREPARATIONS; SCHIZOPHRENIA;

EID: 34047223028     PISSN: 02776715     EISSN: 10970258     Source Type: Journal    
DOI: 10.1002/sim.2636     Document Type: Article

References (33)

1. Grahnén A, Karlsson MO. Concentration-controlled or Effect-controlled trials. Useful alternatives to conventional Dose-Controlled trials? Clinical Pharmacokinetics 2001; 40:317-325.
2. Wilkinson GR. Pharmacokinetics. The dynamics of drug absorption, distribution and elimination. In The Pharmacological Basis of Therapeutics (10th edn), Hardman JG, Limbird LE, Gilman AG (eds). McGraw-Hill: New York, NY, 2001.
3. Vozeh S, Muir KT, Sheiner LB, Follath F. Predicting individual phenytoin dosage. Journal of Pharmacokinetics and Biopharmaceutics 1981; 9:131-146.
4. Sheiner LB, Beal SL. Bayesian individualization of pharmacokinetics: simple implementation and comparison with non-Bayesian methods. Journal of Pharmaceutical Sciences 1982; 71:1344-1348.
5. Vozeh S, Steimer J-L. Feedback control methods for drug dosage optimisation. Concepts, classification and clinical application. Clinical Pharmacokinetics 1985; 10:457-476.
6. Burton ME, Vasko MR, Brater DC. Comparison of drug dosing methods. Clinical Pharmacokinetics 1985; 10:1-37.
7. Peck CC, Rodman JH. Analysis of clinical pharmacokinetic data for individualizing drug dosage regimens. In Applied Pharmacokinetics, Evans WE et al. (eds). Applied Therapeutics: Vancouver, WA, 1990.
8. Sheiner LB, Ludden TM. Population pharmacokinetics/dynamics. Annual Review of Pharmacology and Toxicology 1992; 32:185-209.
9. Jelliffe RW, Schumitzky A, Bayard D, Milman M, Van Guilder M, Wang X, Jiang F, Babaut X, Maire P. Model-based goal-oriented, individualized drug therapy. Linkage of population modeling, new multiple model dosage design, Bayesian feedback and individualized target goals. Clinical Pharmacokinetics 1998; 34:57-77.
10. Wakefield J. An expected loss approach to the design of dosage regimes. The Statistician 1994; 43:13-29.
11. Wakefield J. The Bayesian analysis of population pharmacokinetic models. Journal of the American Statistical Association 1996; 91:62-75.
12. Wakefield J, Bennett J. The Bayesian modeling of covariates for population pharmacokinetic models. Journal of the American Statistical Association 1996; 91:917-927.
13. Rostami-Hodjegan A, Amin AM, Spencer EP, Lennard MS, Tucker GT, Flanagan RJ. Influence of dose, cigarette smoking, age, sex, and metabolic activity on plasma clozapine concentrations: a predictive model and nomograms to aid clozapine dose adjustment and to assess compliance in individual patients. Journal of Clinical Psychopharmacology 2004; 24:70-78.
14. Perry PJ, Bever KA, Arndt S, Combs M. Relationship between patient variables and plasma clozapine concentrations: a dosing nomogram. Biological Psychiatry 1998; 44:733-738.
15. Whiting B, Kelman AW, Grevel J. Population pharmacokinetics. Theory and clinical application. Clinical Pharmacokinetics 1986; 11:387-401.
16. Sheiner LB, Beal SL. Evaluation of methods for estimating population pharmacokinetic parameters. I. Michaelis-Menten model: routine clinical pharmacokinetic data. Journal of Pharmacokinetics and Biopharmaceutics 1980; 8:553-571.
17. Sheiner LB, Beal SL. Evaluation of methods for estimating population pharmacokinetic parameters. II. Biexponential model and experimental pharmacokinetic data. Journal of Pharmacokinetics and Biopharmaceutics 1981; 9:635-651.
18. Haring C, Fleischhacker WW, Schett P, Humpel C, Barnas C, Saria A. Influence of patient-related variables on clozapine plasma levels. American Journal of Psychiatry 1990; 147:1471-1475.
19. Simpson GM, Josiassen RC, Stanilla JK, de Leon J, Nair C, Abraham G, Odom-White A, Turner RM. Double-blind study of clozapine dose response in chronic schizophrenia. American Journal of Psychiatry 1999; 156:1744-1750.
20. Diaz FJ, de Leon J, Josiassen RC, Cooper TB, Simpson GM. Plasma clozapine concentration coefficients of variation in a long term study. Schizophrenia Research 2004; 72:131-135.
21. Winter ME. Basic Clinical Pharmacokinetics (4th edn). Lippincott Williams & Wilkins: Philadelphia, PA, 2004.
22. Olesen OV. Therapeutic drug monitoring of clozapine treatment. Therapeutic threshold value for serum clozapine concentrations. Clinical Pharmacokinetics 1998; 34:497-502.
23. de Leon J, Diaz FJ. Serious respiratory infections can increase clozapine levels and contribute to side effects: a case report. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2003; 27:1059-1063.
24. de Leon J, Diaz FJ, Rogers T, Browne D, Dinsmore L, Ghosheh O, Dwoskin LP, Crooks PA. A pilot study of plasma caffeine concentrations in a US sample of smoker and non-smoker volunteers. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2003; 27:165-171.
25. Verbeke G, Molenberghs G. Linear Mixed Models for Longitudinal Data. Springer: New York, 2000.
26. Muñoz A, Xu J. Models for the incubation of AIDS and variations according to age and period. Statistics in Medicine 1996; 15:2459-2473.
27. Bartko JJ. The intraclass correlation coefficient as a measure of reliability. Psychological Reports 1966; 19:3-11.
28. Casella G, Berger RL. Statistical Inference (2nd edn). Duxbury: Pacific Grove, CA, 2002.
29. Sabaawi M, Singh NN, de Leon J. Guidelines for the use of clozapine in individuals with developmental disabilities. Research in Developmental Disabilities 2006; 27:309-336.
30. SAS Institute. SAS Procedures Guide, ver. 5. SAS Institute Inc: Cary, North Carolina, 1999.
31. Perry PJ, Miller DD, Arndt SV, Cadoret RJ. Clozapine and nor-clozapine plasma concentrations and clinical response of treatment-refractory schizophrenia patients. American Journal of Psychiatry 1991; 148:231-235.
32. Simpson GM, Cooper TA. Clozapine plasma levels and convulsions. American Journal of Psychiatry 1978; 135:99-100.
33. Lehmann EL, Casella G. Theory of Point Estimation (2nd edn). Springer: New York, 1998.